<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360617</url>
  </required_header>
  <id_info>
    <org_study_id>UMC-2017-100</org_study_id>
    <nct_id>NCT03360617</nct_id>
  </id_info>
  <brief_title>Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?</brief_title>
  <acronym>IVP-ABX</acronym>
  <official_title>Safety Comparison of Antibiotics Administered Via Intravenous Push Versus Intravenous Piggyback to Adult Patients in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center of Southern Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center of Southern Nevada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares whether or not a safety difference exists between delivering antibiotics
      via IV push or IV piggyback method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares whether or not a safety difference exists between delivering antibiotics
      via the IV push or IV piggyback method. It will be a single center, prospective,
      double-blinded, double-dummy, randomized controlled trial on a convenience sample of patients
      presenting to the ED receiving select beta-lactam antibiotics. Patients will be randomized to
      IV push antibiotic plus IV piggyback placebo or IV push placebo plus IV piggyback antibiotic.
      Patients will only be enrolled when a pharmacist who is familiar with the study is available
      to prepare medications. Treatment group assignment will be predetermined using an Excel
      random number generator. An investigator will conduct an informed consent with the patient.
      Only the pharmacist will have access to the randomization records and will not reveal the
      randomization until the end of the study. If the patient consents to the study, a pharmacist
      involved in the study will prepare the IV push syringe and IV piggyback. The IV push syringe
      and IV piggyback will be prepared in a manner that makes the contents blinded. Preparation of
      the IV push syringe and IV piggyback are standardized. The syringe and piggyback will be
      handed to the nurse for administration. The IV push antibiotic will be administered over 2-3
      minutes and the IV piggyback antibiotic will be administered over 30 minutes. The IV push and
      IV piggyback will be administered at the same time. A research assistant will conduct surveys
      with the patient at the start of administration and every 15 minutes for a total of 90
      minutes to observe for any adverse drug reactions. During the 90-minute observation period,
      other medications will be allowed to be administered to the patient. All medications received
      during this time period will be documented in the patient data sheet. If an adverse drug
      reaction occurs, the attending physician or medical resident caring for the patient will be
      notified to come evaluate the patient. Adverse drug reaction severity will be determined by
      the attending physician or medical resident based on a predetermined scale. Adverse drug
      reaction information will be collected to determine correlation of adverse drug reaction to
      drug administration. Adverse drug reactions deemed as serious will be reported to the
      Institutional Review Board (IRB) within 5 days of the event.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center, prospective, double-blinded, double-dummy, randomized controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>When the pharmacist prepares the medication he/she will refer to the randomization form to select the correct study arm. The pharmacist will place a protective cover over the syringe and over the piggyback bag before it is provided to the nurse administering the medication.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in number of adverse reactions at 90 minutes from time 0</measure>
    <time_frame>From the time of administration (time 0) to 90 minutes</time_frame>
    <description>The difference in the number of adverse reactions between the study arms within the first 90 minutes following administration of antibiotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in severity of adverse reactions between study arms.</measure>
    <time_frame>90 minutes from drug administration (time 0)</time_frame>
    <description>The difference in severity of adverse reaction between the study arms based on the National Cancer Institute's, Common Terminology Criteria for Adverse Events, v4.0 (2017)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in adverse reaction type between study arms.</measure>
    <time_frame>90 minutes from drug administration (time 0)</time_frame>
    <description>The difference between the study arms for type of adverse reactions based on the National Cancer Institute's, Common Terminology Criteria for Adverse Events, v4.0 (2017)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in hospital length of stay between study arms</measure>
    <time_frame>Time from subject's arrival to Emergency Department (ED) until either discharged from ED to home, or if admitted, hospital discharge up to 90 days from ED admission.</time_frame>
    <description>The difference between the study arms hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of In-Hospital Mortality between study arms</measure>
    <time_frame>Time from the subject's arrival to the Emergency Department (ED) until the subject is pronounced dead up to 90 days from ED admission.</time_frame>
    <description>The difference of in-hospital mortality between the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost comparison between study arms</measure>
    <time_frame>90 minutes from drug administration (time 0)</time_frame>
    <description>A description of the cost of service between the study arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Syringe Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV antibiotics will be delivered by syringe IV push over 2-3 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piggyback Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>IV antibiotics will be delivered by IV piggyback over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe IV Push over 2-3 minutes</intervention_name>
    <description>IV antibiotics will be administered by Syringe IV Push over 2-3 minutes</description>
    <arm_group_label>Syringe Arm</arm_group_label>
    <other_name>IVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Piggyback over 30 minutes</intervention_name>
    <description>IV antibiotics will be administered by IV Piggyback over 30 minutes.</description>
    <arm_group_label>Piggyback Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Patients who present to the adult ED in whom IV aztreonam, cefazolin, cefoxitin,
             ceftriaxone, cefepime, ertapenem, or meropenem is ordered by the treating physician

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Non-English speaking patient

          -  Attending provider excludes patient

          -  Unable to consent

          -  Prisoner

          -  Allergy to any beta-lactam antibiotic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aryan Rahbar, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center of Southern Nevada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wesley J Forred, RN</last_name>
    <phone>702-466-7801</phone>
    <email>wesley.forred@umcsn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yili Gan, MS</last_name>
    <phone>702-383-7336</phone>
    <email>yili.gan@umcsn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center of Southen Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley J Forred, RN</last_name>
      <phone>702-224-7124</phone>
      <email>wesley.forred@umcsn.com</email>
    </contact>
    <contact_backup>
      <last_name>Yili Gan, MA</last_name>
      <phone>702-383-7336</phone>
      <email>yili.gan@umcsn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Ann Pharmacother. 1999 Dec;33(12):1258-61.</citation>
    <PMID>10630824</PMID>
  </reference>
  <reference>
    <citation>Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy. 2013 Mar;33(3):266-74. doi: 10.1002/phar.1197. Epub 2013 Feb 11.</citation>
    <PMID>23400916</PMID>
  </reference>
  <reference>
    <citation>Poole SM, Nowobilski-Vasilios A, Free F. Intravenous push medications in the home. J Intraven Nurs. 1999 Jul-Aug;22(4):209-15.</citation>
    <PMID>10476138</PMID>
  </reference>
  <reference>
    <citation>Butterfield-Cowper JM, Burgner K. Effects of i.v. push administration on Î²-lactam pharmacodynamics. Am J Health Syst Pharm. 2017 May 1;74(9):e170-e175. doi: 10.2146/ajhp150883.</citation>
    <PMID>28438821</PMID>
  </reference>
  <reference>
    <citation>Martz C, Hoesly M, Davis N. Reducing Order to Antibiotic Administration Time in Septic Patients: The Role of IV Push Antibiotics. Unpublished Abstract. Eastern Virginia Medical School Institutional Review Board.</citation>
  </reference>
  <results_reference>
    <citation>Institute for Safe Medication Practices (ISMP, 2015). Safe Practice guidelines for Adult IV Push Medications. Retrieved from http://www.ismp.org/Tools/guidelines/ivsummitpush/ivpushmedguidelines.pdf</citation>
  </results_reference>
  <results_reference>
    <citation>Sanborn M, Gabay M, Moody ML. The Safety of Intravenous Drug Delivery Systems: Update on Current Issues Since the 1999 Consensus Development Conference. Hospital Pharmacy 2009.44(2):159-164</citation>
  </results_reference>
  <results_reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552. doi: 10.1097/CCM.0000000000002255.</citation>
    <PMID>28098591</PMID>
  </results_reference>
  <results_reference>
    <citation>Garrelts JC, Smith DF, Ast D, Peterie JD. A comparison of the safety, timing and cost-effectiveness of administering antibiotics by intravenous bolus (push) versus intravenous piggyback (slow infusion) in surgical prophylaxis. Pharmacoeconomics. 1992 Feb;1(2):116-23.</citation>
    <PMID>10172048</PMID>
  </results_reference>
  <results_reference>
    <citation>Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother. 1995 Jul;36 Suppl A:207-23.</citation>
    <PMID>8543496</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center of Southern Nevada</investigator_affiliation>
    <investigator_full_name>Aryan Rahbar</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>IV</keyword>
  <keyword>Intravenous</keyword>
  <keyword>IV Push</keyword>
  <keyword>Piggyback</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Beta Lactam</keyword>
  <keyword>Infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

